Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dianthus Therapeutics, Inc. (DNTH : NSDQ)

• Company Description    Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $109.13 Daily Weekly Monthly 20 Day Moving Average: 544,881 shares Shares Outstanding: 54.67 (millions) Market Capitalization: $5,965.73 (millions) Beta: 1.24 52 Week High: $117.88 52 Week Low: $30.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.59% 1.31% 12 Week 38.35% 35.43% Year To Date 164.81% 136.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 Times Square 43rd Floor - New York,NY 10036 USA ph: 929-999-4055 fax: - ir@dianthustx.com http://www.dianthustx.com

• General Corporate Information    Officers Marino Garcia - President; Chief Executive Officer and Director Alison Lawton - Chairman Ryan Savitz - Executive Vice President; Chief Financial Officer Edward Carr - Chief Accounting Officer Anne McGeorge - Director Peer Information Dianthus Therapeutics, Inc. (CORR.) Dianthus Therapeutics, Inc. (RSPI) Dianthus Therapeutics, Inc. (CGXP) Dianthus Therapeutics, Inc. (BGEN) Dianthus Therapeutics, Inc. (GTBP) Dianthus Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 252828108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 54.67 Most Recent Split Date: 9.00 (0.06:1) Beta: 1.24 Market Capitalization: $5,965.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.09 Price/Cash Flow: - Price / Sales: 3,133.25 EPS Growth vs. Year Ago Period: -2.27% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: 294.30% vs. Previous Quarter: 64.36% ROE 06/30/26 - -22.53 03/31/26 - -27.30 12/31/25 - -38.85 ROA 06/30/26 - -21.55 03/31/26 - -25.91 12/31/25 - -36.42 Current Ratio 06/30/26 - 26.10 03/31/26 - 29.25 12/31/25 - 13.32 Quick Ratio 06/30/26 - 26.10 03/31/26 - 29.25 12/31/25 - 13.32 Operating Margin 06/30/26 - -10,096.95 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Net Margin 06/30/26 - -10,096.95 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Pre-Tax Margin 06/30/26 - -10,096.95 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Book Value 06/30/26 - 21.44 03/31/26 - 22.06 12/31/25 - 11.41 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©